Amy Chadburn

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma
    Amy Chadburn
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Surg Pathol 28:1401-16. 2004
  2. ncbi HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors
    Bing He
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Immunol 176:3931-41. 2006
  3. pmc Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7
    Kui Nie
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Am J Pathol 177:1470-9. 2010
  4. pmc MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas
    Kui Nie
    Department of Pathology and Laboratory Medicine, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Pathol 173:242-52. 2008
  5. ncbi Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI
    Weifeng Xu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Nat Immunol 8:294-303. 2007
  6. ncbi Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
    John P Leonard
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 10:5327-34. 2004
  7. pmc HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits
    Weifeng Xu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Nat Immunol 10:1008-17. 2009
  8. pmc Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation
    Giorgio Cattoretti
    Institute for Cancer Genetics and the Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Cancer Res 69:8686-92. 2009
  9. doi Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065, USA
    Mod Pathol 22:1507-17. 2009
  10. pmc Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome
    David R Czuchlewski
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Am J Clin Pathol 130:957-62. 2008

Detail Information

Publications66

  1. ncbi KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma
    Amy Chadburn
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Surg Pathol 28:1401-16. 2004
    ..These findings strongly suggest that these decidedly rare KSHV-positive solid lymphomas belong to the spectrum of PEL. Therefore, we propose that the KSHV-positive solid lymphomas be designated extra-cavitary PELs...
  2. ncbi HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors
    Bing He
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Immunol 176:3931-41. 2006
    ..Chronic activation of B cells through this CD40-independent pathway could impair protective T cell-dependent Ab responses by inducing immune exhaustion...
  3. pmc Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7
    Kui Nie
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Am J Pathol 177:1470-9. 2010
    ..These findings provide further evidence for an important role of impairment of terminal B cell differentiation in DLBCL pathogenesis...
  4. pmc MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas
    Kui Nie
    Department of Pathology and Laboratory Medicine, Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Pathol 173:242-52. 2008
    ....
  5. ncbi Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI
    Weifeng Xu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Nat Immunol 8:294-303. 2007
    ..NOTE: In the version of this article initially published online, the middle label above Figure 6c is incorrect. The correct label should be 'BAFF'. The error has been corrected for all versions of the article...
  6. ncbi Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
    John P Leonard
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 10:5327-34. 2004
    ..We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma...
  7. pmc HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits
    Weifeng Xu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Nat Immunol 10:1008-17. 2009
    ....
  8. pmc Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation
    Giorgio Cattoretti
    Institute for Cancer Genetics and the Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Cancer Res 69:8686-92. 2009
    ..The high incidence of DLBCL in S1P(2)(-/-) mice, its onset at old age, and the relative lack of other neoplasms identify these mice as a novel, and potentially valuable, model for this highly prevalent and aggressive human malignancy...
  9. doi Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065, USA
    Mod Pathol 22:1507-17. 2009
    ..The molecular pathogenesis, clinical manifestations, and prognostic significance of these lesions remain to be elucidated...
  10. pmc Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome
    David R Czuchlewski
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Am J Clin Pathol 130:957-62. 2008
    ....
  11. ncbi Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL
    Bing He
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Immunity 26:812-26. 2007
    ..Thus, mucosal vaccines should activate IECs to induce more effective IgA(2) responses...
  12. ncbi Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Jodi V Mones
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 48:342-8. 2007
    ..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses...
  13. pmc Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Medical College, Cornell University, 1300 York Ave, Rm C 410, New York, NY 10021, USA
    Blood 109:729-39. 2007
    ....
  14. doi Outcome of deferred initial therapy in mantle-cell lymphoma
    Peter Martin
    Starr Building Rm 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 27:1209-13. 2009
    ..Because data on observation, or "watch and wait," have not been previously reported, we analyzed the outcome of deferred initial therapy...
  15. pmc Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1
    Kevin N Heller
    Laboratory of Viral Immunobiology, Christopher H Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY, USA
    Int J Cancer 123:2824-31. 2008
    ..These data suggest a selective loss of EBNA1-specific immune control in EBV-associated lymphoma patients, which should be targeted for immunotherapy of these malignancies...
  16. doi Improving outcomes for patients with Burkitt lymphoma and HIV
    Victoria S Blinder
    Divisions of Hematology Oncology and Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA
    AIDS Patient Care STDS 22:175-87. 2008
    ..Further studies, including randomized clinical trials, are needed to better delineate the optimal treatment for patients with this devastating disease...
  17. ncbi Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas
    Wayne Tam
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, K502A, 525 East 68th Street, New York, NY 10021, USA
    Blood 107:4090-100. 2006
    ..It also demonstrates for the first time the potential role of RNA editing in lymphomagenesis...
  18. pmc A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
    Leandro C Cerchietti
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell College of Medicine, New York, NY 10065, USA
    Blood 113:3397-405. 2009
    ..Finally, RI-BPI could kill primary human DLBCL cells but had no effect on normal lymphoid tissue or other tumors...
  19. pmc BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
    Masumichi Saito
    Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 106:11294-9. 2009
    ..These results identify an important function for BCL6 in facilitating apoptosis of GC B cells via suppression of BCL2, and suggest that blocking this pathway is critical for lymphomagenesis...
  20. doi Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
    Jia Ruan
    Center for Lymphoma and Myeloma, Weill Cornell Medical College, 525 East 68th St, Starr 340, New York, NY 10065, USA
    J Clin Oncol 29:690-7. 2011
    ..We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)...
  21. pmc Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas
    Yao Tseng Chen
    Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:3093-8. 2010
    ....
  22. ncbi Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 23:5044-51. 2005
    ..To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL)...
  23. ncbi Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
    Rebecca L Elstrom
    Center for Lymphoma and Myeloma, Weill Cornell Medical Center, New York, NY 10021, USA
    Clin Lymphoma Myeloma Leuk 10:192-6. 2010
    ..Chemotherapy responsiveness before transplantation is a major predictor of outcome. Patients not responding to second-line regimens may receive third-line therapy in the hopes of achieving response, but outcome data are limited...
  24. pmc Analysis of the coding genome of diffuse large B-cell lymphoma
    Laura Pasqualucci
    Institute for Cancer Genetics, Columbia University, New York, New York, USA
    Nat Genet 43:830-7. 2011
    ..These results provide initial data on the complexity of the DLBCL coding genome and identify novel dysregulated pathways underlying its pathogenesis...
  25. pmc Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma
    Daniel L Di Bartolo
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    J Virol 83:4308-15. 2009
    ..Our data suggest that Oct-2 downregulation in infected cells would be favorable to KSHV in allowing for efficient viral reactivation...
  26. ncbi Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells
    Xugang Qiao
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Nat Immunol 7:302-10. 2006
    ..Thus, human immunodeficiency virus 1 may evade protective T cell-dependent IgG and IgA responses by 'hijacking' physiological feedback inhibitors in B cells via Nef...
  27. ncbi Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals
    Y Lynn Wang
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Acta Haematol 118:209-14. 2007
    ..The JAK2(V617F) mutation, which has been found in patients with myeloproliferative disorders (MPD), has not yet been evaluated in lymphoproliferative disorders by any adequately sensitive techniques...
  28. ncbi Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 23:5696-704. 2005
    ..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma...
  29. pmc Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism
    Chunyan Yang
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Am J Pathol 170:722-32. 2007
    ..These findings highlight the need for further investigation into the role of PPARgamma in cancer before widespread use of its agonists as anticancer therapeutics...
  30. pmc A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma
    Lisa Giulino
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 117:4852-4. 2011
    ..In ARLs loss of A20 may be an alternative mechanism of NF-κB activation in the absence of latent membrane protein 1 expression...
  31. doi FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma
    Sarah C Rutherford
    Centre for Lymphoma and Myeloma, Division of Haematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 49:719-26. 2008
    ..Our findings support a potential role for preoperative FDG-PET in consideration of the need for splenectomy in these settings...
  32. pmc Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
    Till Strowig
    Laboratory of Viral Immunobiology, Christopher H Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 206:1423-34. 2009
    ..Both loss of CD4(+) and CD8(+) T cells abolished immune control. Therefore, this mouse model recapitulates features of symptomatic primary EBV infection and generates T cell-mediated immune control that resists oncogenic transformation...
  33. pmc Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034
    Amy Chadburn
    Weill Cornell Medical College, New York, NY 10065, USA
    J Clin Oncol 27:5039-48. 2009
    ..We sought to determine whether immunohistochemical analyses of biopsies from patients with DLBCL having HIV infection are similarly relevant for prognosis...
  34. pmc Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma
    Mara Compagno
    Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Nature 459:717-21. 2009
    ..Thus, our results demonstrate that NF-kappaB activation in DLBCL is caused by genetic lesions affecting multiple genes, the loss or activation of which may promote lymphomagenesis by leading to abnormally prolonged NF-kappaB responses...
  35. pmc Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia
    Ilaria V Libani
    Department of Pediatric Hematology Oncology, Children s Cancer and Blood Foundation Laboratories, Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 112:875-85. 2008
    ..In addition, these results suggest that use of Jak2 inhibitors has the potential to profoundly change the management of this disorder...
  36. ncbi Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma
    Jia Ruan
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5622-31. 2006
    ..Here, we investigated whether stromal incorporation of CD68(+) hemangiogenic cells and alpha-smooth muscle actin(+) (alpha-SMA(+)) stromal cells correlates with neoangiogenesis and progression in human non-Hodgkin's lymphoma subtypes...
  37. pmc Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association
    Wen Fan
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021, USA
    J Virol 79:1244-51. 2005
    ..Within the KSHV-positive PELs, the effect of EBV is more subtle but nevertheless clear...
  38. pmc Inactivating mutations of acetyltransferase genes in B-cell lymphoma
    Laura Pasqualucci
    Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Nature 471:189-95. 2011
    ..These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin's lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms...
  39. ncbi The stromal composition of mast cell aggregates in systemic mastocytosis
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Mod Pathol 22:857-65. 2009
    ....
  40. pmc BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma
    Jonathan Mandelbaum
    Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Cancer Cell 18:568-79. 2010
    ..These results demonstrate that BLIMP1 is a bona fide tumor-suppressor gene whose loss contributes to lymphomagenesis by blocking plasma cell differentiation...
  41. pmc CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Sergey V Shmelkov
    Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:2111-20. 2008
    ....
  42. pmc Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin
    Sara Gardenghi
    Department of Pediatric Hematology Oncology, Children s Blood Foundation Laboratories, Weill Medical College of Cornell University, 515E 71st Street S702, New York, NY 10021, USA
    Blood 109:5027-35. 2007
    ....
  43. ncbi Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders
    Roland G Nador
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Am J Surg Pathol 27:293-302. 2003
    ..As in the case of their polymorphic PT-LPD counterparts, their malignant status, biologic significance, and relationship to monomorphic B-cell lymphomas remain to be elucidated...
  44. ncbi Genetics of follicular lymphoma transformation
    Laura Pasqualucci
    Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA Electronic address
    Cell Rep 6:130-40. 2014
    ..The genomic profile of tFL shares similarities with that of germinal center B cell-type de novo DLBCL but also displays unique combinations of altered genes with diagnostic and therapeutic implications. ..
  45. ncbi ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
    Nathalie Chevallier
    Department of Medicine, Mount Sinai School of Medicine, One Gustave Levy Pl, New York, NY 10029, USA
    Blood 103:1454-63. 2004
    ..Therefore, ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematologic malignancies...
  46. pmc KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor
    Daniel L Di Bartolo
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    Blood 111:4731-40. 2008
    ....
  47. ncbi Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease
    Lauren K Schwartz
    Division of Gastroenterology, Mount Sinai School of Medicine, New York, 10021, USA
    Clin Gastroenterol Hepatol 4:1030-4. 2006
    ..Such patients may warrant more aggressive diagnostic surveillance and evaluation...
  48. ncbi Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma
    April Chiu
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Cancer Treat Res 131:1-48. 2006
  49. ncbi Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA
    J Clin Oncol 21:3051-9. 2003
    ..This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL)...
  50. ncbi Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
    Bing He
    Departments of Pathology and Laboratory Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Immunol 172:3268-79. 2004
    ..Thus, neutralization of BAFF and APRIL by soluble TACI and BCMA decoy receptors could be useful to dampen the accumulation of malignant B cells in NHL patients...
  51. pmc DNA polymerase mu gene expression in B-cell non-Hodgkin's lymphomas: an analysis utilizing in situ hybridization
    April Chiu
    Department of Pathology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Pathol 161:1349-55. 2002
    ....
  52. ncbi Splenic cord capillary hemangioma and anemia: resolution after splenectomy
    Meredith Kato
    Department of Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Hematol 81:538-42. 2006
    ..Cord capillary hemangiomas are exceedingly rare with few reports in the literature. This is the first reported case of resolution of anemia after splenectomy for a vascular tumor of the spleen...
  53. ncbi Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts
    Ulf Klein
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Blood 101:4115-21. 2003
    ..Finally, our results identify a set of genes specifically expressed in PEL tumor cells. Their expression was validated at the protein level, suggesting their potential pathogenetic and clinical significance...
  54. ncbi Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature
    Neal Luther
    Department of Neurological Surgery, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA
    J Neurooncol 75:185-8. 2005
    ..Although rare, CNS invasion portends a poor prognosis, emphasizing the importance of early and accurate immunophenotype profiling and the need for novel, aggressive therapy...
  55. ncbi Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV
    Andrew H Talal
    Department of Medicine, Weill Medical College of Cornell University, New York City, NY, USA
    J Acquir Immune Defic Syndr 35:103-13. 2004
    ....
  56. ncbi The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    Eric Feldman
    The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 31:702-7. 2003
    ..To describe clinical and laboratory features of a cohort of patients with chronic myelogenous leukemia (CML) who developed Ph(-), trisomy 8(+) metaphases while on treatment with imatinib mesylate...
  57. ncbi Lymphoid malignancies: immunophenotypic analysis
    Amy Chadburn
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Adv Clin Chem 37:293-353. 2003
  58. ncbi Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene
    Chad May
    Department of Human Genetics Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 99:1902-8. 2002
    ..These results demonstrate for the first time that viral-mediated globin gene transfer in hematopoietic stem cells effectively treats a severe hemoglobin disorder...
  59. ncbi Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B-cell lymphomas
    Wayne Tam
    Genes Chromosomes Cancer 46:416-8. 2007
  60. ncbi Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda
    Eric A Engels
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20892, USA
    Hum Pathol 38:308-14. 2007
    ..We describe the first case of a KSHV-positive NHL from this region; this case is also the first reported pediatric lymphoma associated with KSHV infection...
  61. ncbi Eosinophilic variant of chronic myeloid leukemia with vascular complications
    Vladimir Gotlib
    Division of Hematology Oncology, The Brooklyn Hospital Center, 121 DeKalb Ave, Brooklyn, NY 11201, USA
    Leuk Lymphoma 44:1609-13. 2003
    ..Despite an almost complete response to CML treatment with Gleevac, combined with prednisone, aspirin and coumadin the patient sustained irreversible damage to the vascular lining of the distal arteries of the upper extremities...
  62. pmc Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
    Lawrence D Kaplan
    Division of Hematology Oncology, University of California, 400 Parnassus Ave, Rm A 502, San Francisco, CA 94143, USA
    Blood 106:1538-43. 2005
    ..However, these benefits may be offset by an increase in infectious deaths, particularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3)...
  63. ncbi CD44 loss in gastric stromal tumors as a prognostic marker
    Elizabeth Montgomery
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 28:168-77. 2004
    ..Thus, the prognostic value of CD44s and isoform expression in GIST were evaluated by immunohistochemistry of tissue microarrays...
  64. pmc Accumulation of miR-155 and BIC RNA in human B cell lymphomas
    Peggy S Eis
    Department of Biomolecular Chemistry, University of Wisconsin Medical School, 1300 University Avenue, Madison, WI 53706, USA
    Proc Natl Acad Sci U S A 102:3627-32. 2005
    ..Because patients with activated B cell-type DLBCL have a poorer clinical prognosis, quantification of this microRNA may be diagnostically useful...
  65. ncbi Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes
    Vladimir Gotlib
    Division of Hematology Oncology, The Brooklyn Hospital Center, New York 11201, USA
    Leuk Lymphoma 43:1337-40. 2002
    ..The patient improved after treatment with a combination of radiation and chemotherapy...
  66. doi Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium
    Brett T Brinker
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer 112:1083-8. 2008
    ....